Author

J. Ravetch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

D. A. Knorr· 2 shared A. Jones· 1 shared B. D. Piening· 1 shared B. Fox· 1 shared C. Ballesteros-Merino· 1 shared C. Bifulco· 1 shared D. Sprott· 1 shared J. C. Osorio· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. A. Knorr

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

J. C. Osorio, P. Smith, D. A. Knorr, J. Ravetch

This study shows that anti-CD47 antibodies' antitumor activity depends on Fc-FcγR interactions, using a humanized mouse model to demonstrate enhanced immune responses with Fc-engineered antibodies.

bioRxiv · Jun 29, 2023Immunology

FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies

D. A. Knorr, R. Leidner, S. Jensen, R. Meng, A. Jones, C. Ballesteros-Merino, R. B. Bell, M. Baez, D. Sprott, C. Bifulco, B. D. Piening, R. Dahan, B. Fox, J. Ravetch

This paper identifies FcyRIIB as an inhibitory Fc receptor limiting Treg depletion by anti-CTLA-4 antibodies and shows Fc engineering can enhance their efficacy.

bioRxiv · Jan 19, 2023 · PreprintImmunology